"Establish an immunological-based platform for nano drug: 1. Establish macrophages as an in vitro cell-based testing platform 2. Safety assessmentimmunomodulatory effects of nano drugs 3. Gold nanodots as a specific target of Nrf2 pathway against chronic diseases."

The bioactive corecorona synergism of sub-nanometer gold enables slowed inflammationincreased tissue regeneration in wound hypoxia. The developed dual-function wound dressing based on a gold nanocluster with a plane structurean adhesive layer presented two features: (1) the gold nanocluster can attenuate the inflammatory response by adjusting the strength of the active site (i.e., l

A novel “Platform Technology” in surgical hemostasis, based on biodegradable polyurethane particles with anti-inflammatory and nerve repair, not only accelerates wound healing but also provides solutions for hemostasis during surgery, and improve biocompatibility and adverse of commercially hemostats to achieve the best patient care. Our first product is aimed to provide a hemostatic agent, use on the bleeding surface and deep, with additional functions to surgeons, which allows customers to shorten the operation time, reduce stay in the hospital, and reduce the chance of secondary surgery.

"1. New method to prepare (3S, 3’S)astaxanthin, with high yield, high stabilityharmless to organism 2. The method has variety of biological activities anti-oxidation, anti-agingpromote damage tissue repair 3. It has anti-cancer potential, especially effective against metastatic cancer cells 4. Applied as Multifunctional medical supplies, functional foods, functional drinks, cosmeticsmaintenance products"

We developed Polypyrrole (PPy) based NIR-photothermal related platform technologies. This photothermal driving hyperthermia carrier systems are biocompatible are able to possess versatile functions in anticancer, antibacterial, thrombolysis, wound-healingsuppression of inflammation related bioengineering potential applications. These innovative works shed light on the efficacy of combining photothermal-performance with translational manner in biomedical, clinicalindustrial designs.

Ninety percent of human diseases are related to abnormal inflammation. WJM team has successfully developed a new monoclonal antibody that can inhibit a key inflammation protein. Animal experiments have accumulated more than ten disease modes, including a variety of solid tumors, fibrosis, degenerativecardiovascular diseases. This antibody is qualified as an orphan drug for the treatment of IPF. New coronary pneumonia has greatly increased the demand for pulmonary fibrosis treatment,has also become an important target for mergersacquisitions of global pharmaceutical companies.